about
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesDiscordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesAdjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGunBalance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responsesNeutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 AcquisitionCholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.Neutralization of HIV by antibodies.Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region.Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin.Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine.Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.F-106 Transition state Gp120 structures as HIV vaccinesG-111 DNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge
P50
Q27675486-66A20A94-8A46-434C-97D7-2C3FFC16E4EFQ28259999-6F7B88E4-CA6A-4878-89B0-6B7A89F87CB5Q33274285-304827C3-F173-4408-B3B9-57AD878448C4Q33410222-FEC84972-260F-40B5-BEC2-CE32FE9451CFQ33930664-BF34D580-FC6D-4A0E-AF74-D96BED500F2DQ34619929-DC6E550B-0ACF-4015-9DB0-788F9BDE2E7EQ35032794-D2A190CD-757B-416E-933B-575537F406A3Q35066456-3833E73C-4771-4499-8D32-127DE6996644Q35156935-F6D326E9-7F96-4EA1-8D15-A8EE79350FF7Q35165404-03646B56-165B-4250-983F-596E9184887CQ36141515-52BA5995-9C79-4D10-BB62-2E4DAFF90956Q36256348-796FC174-CA4C-4860-801D-5C3ED8FCA918Q36366296-E1025023-EDD2-4A36-B7B9-E60BE01BD5BCQ36496923-911D9684-2C15-4B13-A027-7F0FB450BF66Q37261545-3A09FE6A-A37C-4164-90DA-C56180DF91BAQ39656632-15166092-72F5-4145-9103-68300B56922AQ39668082-8B140675-D400-4021-964E-A44D59E3D575Q39878211-2184B770-3A96-4677-8CB3-D507CD1AA33FQ40626990-204A746E-F09E-4550-8843-2CFE402D9C7CQ40730039-42F3BA63-D1C2-4636-80A2-3A6BF6B402BEQ41039433-E6ABF0EC-BD61-4833-9963-F32B4FBCB138Q45722955-75521F33-8132-4754-929A-C7321D3318C2Q45790603-7628048A-E1AC-4515-BF9C-C4D450F69FDFQ48014958-B416EA48-F1D8-4EA2-9BFF-5623796B3EE2Q60429521-97665EC4-A56A-42CA-BBBF-716127A67ED1Q60429523-0475E97F-60F2-4B18-BCA1-EBAF7CC1D93B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Timothy Fouts
@ast
Timothy Fouts
@en
Timothy Fouts
@es
Timothy Fouts
@nl
Timothy Fouts
@sl
type
label
Timothy Fouts
@ast
Timothy Fouts
@en
Timothy Fouts
@es
Timothy Fouts
@nl
Timothy Fouts
@sl
prefLabel
Timothy Fouts
@ast
Timothy Fouts
@en
Timothy Fouts
@es
Timothy Fouts
@nl
Timothy Fouts
@sl
P108
P106
P108
P1153
6603607043
P21
P31
P496
0000-0002-2429-2859